5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaAirway Obstruction, Dyspnea, Hypersensitivity, Immediate, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Hypersensitivity, Respiratory Sounds, Signs and Symptoms, Signs and Symptoms, Respiratory, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory failure, respiratory system disorderRecruitingPhase 22026-10-05NCT06977581
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-09-28NCT07144280
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesHealthyRecruitingPhase 32026-09-25NCT07160244
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-09-25NCT06758401
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseInfections, Mononegavirales infectious disease, Paramyxoviridae infectious disease, Pneumovirus Infections, RNA Virus Infections, respiratory syncytial virus infectious disease, viral infectious diseaseRecruitingPhase 32026-09-24NCT06866405